These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1225 related articles for article (PubMed ID: 21376385)

  • 21. Advances in therapy: eribulin improves survival for metastatic breast cancer.
    Morris PG
    Anticancer Drugs; 2010 Nov; 21(10):885-9. PubMed ID: 20838209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
    Cortes J; Lorca R
    Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
    Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
    Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
    Muss H; Cortes J; Vahdat LT; Cardoso F; Twelves C; Wanders J; Dutcus CE; Yang J; Seegobin S; O'Shaughnessy J
    Oncologist; 2014 Apr; 19(4):318-27. PubMed ID: 24682463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
    Donoghue M; Lemery SJ; Yuan W; He K; Sridhara R; Shord S; Zhao H; Marathe A; Kotch L; Jee J; Wang Y; Zhou L; Adams WM; Jarral V; Pilaro A; Lostritto R; Gootenberg JE; Keegan P; Pazdur R
    Clin Cancer Res; 2012 Mar; 18(6):1496-505. PubMed ID: 22282463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
    Paillard MJ; Curtit E; Dobi E; Mansi L; Bazan F; Villanueva C; Chaigneau L; Montcuquet P; Meneveau N; Thiery-Vuillemin A; Nerich V; Pivot X
    Bull Cancer; 2015 Sep; 102(9):737-48. PubMed ID: 26022285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
    Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
    Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
    Cortes J; Hudgens S; Twelves C; Perez EA; Awada A; Yelle L; McCutcheon S; Kaufman PA; Forsythe A; Velikova G
    Breast Cancer Res Treat; 2015 Dec; 154(3):509-20. PubMed ID: 26567010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
    Kaufman PA; Awada A; Twelves C; Yelle L; Perez EA; Velikova G; Olivo MS; He Y; Dutcus CE; Cortes J
    J Clin Oncol; 2015 Feb; 33(6):594-601. PubMed ID: 25605862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    Iizumi S; Shimoi T; Tsushita N; Bun S; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    BMC Cancer; 2017 Dec; 17(1):819. PubMed ID: 29202787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eribulin mesylate for the treatment of late-stage breast cancer.
    Gourmelon C; Frenel JS; Campone M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.
    Aogi K; Iwata H; Masuda N; Mukai H; Yoshida M; Rai Y; Taguchi K; Sasaki Y; Takashima S
    Ann Oncol; 2012 Jun; 23(6):1441-8. PubMed ID: 21989327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
    Krop IE; Kim SB; González-Martín A; LoRusso PM; Ferrero JM; Smitt M; Yu R; Leung AC; Wildiers H;
    Lancet Oncol; 2014 Jun; 15(7):689-99. PubMed ID: 24793816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
    Miyoshi Y; Yoshimura Y; Saito K; Muramoto K; Sugawara M; Alexis K; Nomoto K; Nakamura S; Saeki T; Watanabe J; Perez-Garcia JM; Cortes J
    Breast Cancer; 2020 Jul; 27(4):706-715. PubMed ID: 32133606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
    Dranitsaris G; Beegle N; Kalberer T; Blau S; Cox D; Faria C
    J Oncol Pharm Pract; 2015 Jun; 21(3):170-7. PubMed ID: 24620009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
    Twelves C; Cortes J; Vahdat L; Olivo M; He Y; Kaufman PA; Awada A
    Breast Cancer Res Treat; 2014 Dec; 148(3):553-61. PubMed ID: 25381136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.